Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance - Progress and prospects

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 11, 2014, Pages 1253-1265

  Jones, G R ^a   Kennedy, N A ^a   Lees, C W ^a   Arnott, I D ^a   Satsangi, J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALGRANULIN; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; INTESTINE RESECTION; MEDICAL PRACTICE; META ANALYSIS (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REVIEW; RISK ASSESSMENT; RUTGEERTS ENDOSCOPIC GRADING SCALE; SMOKING; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

6-MERCAPTOPURINE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900000652     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12743     Document Type: Review

References (48)

1. Solberg IC, Vatn MH, Høie O, et al,. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
2. Bernell OO, Lapidus AA, Hellers GG,. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
3. Farmer RGR, Whelan GG, Fazio VWV,. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-25.
4. Cosnes JJ, Nion-Larmurier II, Beaugerie LL, Afchain PP, Tiret EE, Gendre JPJ,. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
5. Ramadas AV, Gunesh S, Thomas GAO, Williams GT, Hawthorne AB,. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
6. Olaison GG, Smedh KK, Sjödahl RR,. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-5.
7. Rutgeerts PP, Geboes KK, Vantrappen GG, Kerremans RR, Coenegrachts JLJ, Coremans GG,. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665-72.
8. Williams JG, Wong WD, Rothenberger DA, Goldberg SM,. Recurrence of Crohn's disease after resection. Br J Surg 1991; 78: 10-9.
9. Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP,. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment Pharmacol Ther 2011; 33: 707-13.
10. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P,. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-7.
11. Rutgeerts PP, Geboes KK, Vantrappen GG, Beyls JJ, Kerremans RR, Hiele MM,. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63.
12. Van Assche G, Dignass A, Reinisch W, et al,. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
13. Viscido A, Corrao G, Taddei G, Caprilli R,. "Crohn's disease activity index" is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. Gruppo Italiano per lo Studio del Colon e del Retto. Ital J Gastroenterol Hepatol 1999; 31: 274-9.
14. Walters TD, Steinhart AH, Bernstein CN, et al,. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 2011; 17: 1547-56.
15. Lamb CAC, Mohiuddin MKM, Gicquel JJ, et al,. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 2009; 96: 663-74.
16. Orlando AA, Modesto II, Castiglione FF, et al,. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006; 10: 17-22.
17. Papay P, Reinisch W, Ho E, et al,. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol 2009; 105: 1158-64.
18. Ardizzone S, Maconi G, Sampietro GM, et al,. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127: 730-40.
19. D'Haens GR, Vermeire S, Van Assche G, et al,. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135: 1123-9.
20. Hanauer SB, Korelitz BI, Rutgeerts P, et al,. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology 2004; 127: 723-9.
21. Regueiro M, Schraut W, Baidoo L, et al,. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-50.
22. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L,. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 2012; 35: 625-33.
23. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC,. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; 4: CD006873.
24. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
25. Rutgeerts PP, Hiele MM, Geboes KK, et al,. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-21.
26. Rutgeerts PP, Van Assche GG, Vermeire SS, et al,. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-61.
27. Herfarth H, Tjaden C, Lukas M, et al,. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 2006; 55: 1525-6.
28. Reinisch W, Angelberger S, Petritsch W, et al,. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-9.
29. Domènech E, Mañosa M, Bernal I, et al,. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: Results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis 2008; 14: 508-13.
30. Mañosa M, Cabré E, Bernal I, et al,. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease. Inflamm Bowel Dis 2013; 19: 1889-95.
31. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al,. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-96.
32. Shen FC, Zhang HJ, Zhao XD, Cao RS, Shi RH,. Purine analogues compared with mesalamine or 5-ASA for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Int J Clin Pract 2012; 66: 758-66.
33. Yoshida K, Fukunaga K, Ikeuchi H, et al,. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012; 18: 1617-23.
34. Sorrentino DD, Terrosu GG, Avellini CC, Maiero SS,. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 167: 1804-7.
35. Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D,. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 591-9.
36. Aguas M,. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol 2012; 18: 4391.
37. Savarino E, Dulbecco P, Bodini G, Assandri L, Savarino V,. Prevention of postoperative recurrence of Crohn's disease by Adalimumab. Eur J Gastroenterol Hepatol 2012; 4: 468-70.
38. Papamichael K, Archavlis E, Lariou C, Mantzaris GJ,. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis 2012; 6: 924-31.
39. UK IBD Audit Steering Group. 3rd Round UK IBD audit: report of the results for the national clinical audit of adult inflammatory bowel disease inpatient care in the UK, February, 2012. Royal College of Physicians.
40. Yamamoto T,. Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. World J Gastroenterol 2010; 16: 5405-10.
41. Yamamoto T, Keighley MR,. Smoking and disease recurrence after operation for Crohn's disease. Br J Surg 2000; 87: 398-404.
42. Yamamoto T, Allan RN, Keighley MR,. Smoking is a predictive factor for outcome after colectomy and ileorectal anastomosis in patients with Crohn's colitis. Br J Surg 1999; 86: 1069-70.
43. Lindberg E, Järnerot G, Huitfeldt B,. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 779-82.
44. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP,. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213-21.
45. Nunes T, Etchevers MJ, Merino O, et al,. High smoking cessation rate in Crohn's disease patients after physician advice-the TABACROHN Study. J Crohns Colitis 2013; 7: 202-7.
46. Kennelly RP, Subramaniam T, Egan LJ, Joyce M,. Smoking and Crohn's disease: active modification of an independent risk factor (Education alone is not enough). J Crohns Colitis 2013; 7: 631-5.
47. Biroulet LP, Khosrotehrani K, Carrat F, et al,. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-5.
48. Nos PP, Hinojosa JJ, Aguilera VV, et al,. Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease. Gastroenterol Hepatol 2000; 23: 374-8.